X

Trial Profile

Pilot Study: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium nitrite (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Nitric Oxide Innovations

Most Recent Events

02 Dec 2022 Status changed from recruiting to discontinued.
27 Sep 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
27 Sep 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com